Piracetam, 400 mg capsules 60 pcs

Pharmacotherapeutic group:

Notropic agent.

ATX code

[N06BX03].

Pharmacological properties

Pharmacodynamics

Piracetam is a cyclic derivative of gamma-aminobutyric acid (GABA), is a nootropic agent that directly affects the brain, improves cognitive processes (learning ability, memory, attention, mental performance). It affects the central nervous system in different ways: it changes the speed of excitation distribution in the brain, improves metabolic processes in nerve cells, improves microcirculation, affecting blood rheological characteristics and does not cause vasodilation.

Piracetam inhibits platelet aggregation and restores the elasticity of the red blood cell membrane, reduces red blood cell adhesion. At a dose of 9.6 g, it reduces the level of fibrinogen and Willibrand factors, prolongs the bleeding time.

It improves interhemispheric connections in the brain and synaptic conduction in the neocortical structures.

Piracetam has a protective and restorative effect in cases of brain dysfunction due to hypoxia and intoxication.

Limits the severity and duration of vestibular nystagmus.

Pharmacokinetics

In oral administration the drug is quickly and almost completely absorbed, the peak concentration is reached 1 hour after administration. The bioavailability of the drug is approximately 100%. After a single dose of 2 g the maximum concentration is 40-60 mcg/ml, which is reached in blood after 30 minutes and after 5 hours in cerebrospinal fluid after intravenous injection. Estimated volume of distribution of piracetam is about 0.6 l/kg. Period of half-life of the drug from plasma is 4-5 hours and 8.5 hours from cerebrospinal fluid, which is prolonged in case of renal insufficiency. Pharmacokinetics of piracetam does not change in patients with hepatic insufficiency.

It penetrates through the blood-brain and placental barrier and membranes used in hemodialysis. In animal studies piracetam selectively accumulates in tissues of the cerebral cortex, mainly in the frontal, parietal and occipital lobes, cerebellum and basal ganglia. It does not bind with blood plasma proteins and is not metabolized in the body. 80-100% of piracetam is excreted unchanged by the kidneys through renal filtration. Renal clearance of piracetam in healthy volunteers is 86 ml/min.

Indications

Symptomatic treatment of psychoorganic syndrome, in particular in elderly patients suffering from memory loss, dizziness, decreased concentration and general activity, mood changes, behavior disorder, gait disturbance, as well as in patients with Alzheimer’s disease and senile dementia of the Alzheimer’s type.

The consequences of ischemic stroke are speech disorders, emotional disturbances, decreased motor and mental activity.

Chronic alcoholism – for the treatment of psychoorganic and withdrawal syndromes.

The recovery period after brain injuries and intoxications.

Dizziness and related balance disorders, with the exception of dizziness of vasomotor and mental origin.

As part of complex therapy for learning disabilities in children with psychoorganic syndrome.

For the treatment of cortical myoclonus as mono- or complex therapy.

In the complex therapy of sickle cell anemia.

Pharmacological effect

Pharmacotherapeutic group:

nootropic agent.

ATX code

[N06BX03].

Pharmacological properties

Pharmacodynamics

Piracetam, a cyclic derivative of gamma-aminobutyric acid (GABA), is a nootropic drug that directly affects the brain, improves cognitive processes (learning ability, memory, attention, mental performance). It affects the central nervous system in various ways: it changes the speed of propagation of excitation in the brain, improves metabolic processes in nerve cells, improves microcirculation, affecting the rheological characteristics of the blood and does not cause vasodilation.

Piracetam inhibits platelet aggregation and restores the elasticity of the erythrocyte membrane, reduces the adhesion of erythrocytes. At a dose of 9.6 g, it reduces the level of fibrinogen and von Willibrand factors and prolongs bleeding time.

Improves interhemispheric connections in the brain and synaptic conduction in neocortical structures.

Piracetam has a protective and restorative effect in cases of impaired brain function due to hypoxia and intoxication.

Reduces the severity and duration of vestibular nystagmus.

Pharmacokinetics

When the drug is taken orally, it is quickly and almost completely absorbed, peak concentrations are reached 1 hour after administration. The bioavailability of the drug is approximately 100%. After taking a single dose of 2 g, the maximum concentration is 40-60 mcg/ml, which is achieved in the blood after 30 minutes and 5 hours in the cerebrospinal fluid after intravenous administration. The apparent volume of distribution of piracetam is about 0.6 l/kg. The half-life of the drug from blood plasma is 4-5 hours and 8.5 hours from cerebrospinal fluid, which is prolonged in case of renal failure. The pharmacokinetics of piracetam does not change in patients with liver failure.

Penetrates the blood-brain and placental barrier and membranes used in hemodialysis. In animal studies, piracetam selectively accumulates in the tissues of the cerebral cortex, mainly in the frontal, parietal and occipital lobes, cerebellum and basal ganglia. Does not bind to blood plasma proteins and is not metabolized in the body. 80-100% of piracetam is excreted unchanged by the kidneys by renal filtration. The renal clearance of piracetam in healthy volunteers is 86 ml/min.

Special instructions

Prescribe with caution to patients with impaired hemostasis, before upcoming major surgery or in patients with symptoms of severe bleeding.

When treating cortical myoclonus, abrupt cessation of treatment should be avoided, because this may cause the attacks to recur.
When treating veno-occlusive crisis in sickle cell anemia, a dose of less than 160 mg/kg or irregular use of the drug may cause a relapse of the crisis.

During long-term therapy in elderly patients, regular monitoring of renal function is recommended; if necessary, dose adjustment is carried out depending on QC.

Penetrates through the filter membranes of hemodialysis machines.

During the treatment period, care must be taken when driving vehicles and engaging in other potentially hazardous activities that require increased concentration and speed of psychomotor reactions.

Active ingredient

Piracetam

Composition

One capsule contains:

active ingredient: piracetam – 0.4 g.

Excipients: aerosil, microcrystalline cellulose.

Contraindications

Individual intolerance to piracetam or pyrrolidone derivatives, as well as other components of the drug.

Acute cerebrovascular accident (hemorrhagic stroke).

End-stage renal failure (with creatinine clearance less than 20 ml/min).

Children’s age up to 1 year.

Pregnancy and lactation.

Piracetam penetrates the placental barrier and into breast milk. The concentration of the drug in newborns reaches 70-90% of its concentration in the mother’s blood. Except in special circumstances, Piracetam should not be prescribed during pregnancy. You should refrain from breastfeeding when a woman is prescribed piracetam.

Side Effects

From the side of the central nervous system: motor disinhibition, irritability, drowsiness, depression, asthenia, headache, insomnia, mental agitation, imbalance, ataxia, exacerbation of epilepsy, anxiety, hallucinations, confusion.

From the digestive system: nausea, vomiting, diarrhea, abdominal pain.

Metabolism: increased body weight.

From the senses: vertigo.

From the skin: dermatitis, itching, urticaria.

Allergic reactions: hypersensitivity, anaphylactic reactions, angioedema.

Local reactions: pain at the injection site, thrombophlebitis

Other (with parenteral administration): fever, decreased blood pressure.

Interaction

When used simultaneously with iodine-containing thyroid hormones, confusion, irritability and sleep disturbance may occur.

In high doses (9.6 g/day) in patients with venous thrombosis, it increases the anticoagulant effect of indirect anticoagulants (a more pronounced decrease in platelet aggregation, fibrinogen content, von Willebrand factor, blood and plasma viscosity).

Pharmaceutically compatible with solutions of dextrose (5%, 10%, 20%), fructose (5%, 10%, 20%), 0.9% NaCl solution, Ringer’s solution, 20% mannitol solution, hydroxyethyl starch (6%, 10%).

Overdose

Symptoms: abdominal pain, bloody diarrhea.

Treatment: induction of vomiting, gastric lavage, symptomatic therapy, hemodialysis (effectiveness 50-60%). There is no specific antidote.

Storage conditions

List B. In a dry place, protected from light and out of reach of children, at a temperature not exceeding 25°C.

Shelf life

3 years. Do not use after the date indicated on the package.

Manufacturer

Ozon, Russia